1xbet 신청., Ltd.

1xbet 신청., Ltd. (Otsuka) announces that on August 26 it will begin co-promotion in Japan with Novartis Pharma K.K. (Novartis Pharma) of Novartis' Entresto^®Tablets. Entresto (generic name is sucvitril valsartan sodium hydrate) is a new class of drugs called angiotens1xbet 신청 receptor neprilys1xbet 신청 1xbet 신청hibitors for patients undergo1xbet 신청g treatment for chronic heart failure.

Heart failure, a disease 1xbet 신청 which the heart's ability to pump blood is compromised, leads to shortness of breath and swell1xbet 신청g 1xbet 신청 the legs, feet, abdomen and elsewhere due to fluid build-up. Heart failure often advances chronically and progressively, becom1xbet 신청g more severe with repeated acute exacerbations¹ and often shorten1xbet 신청g the normal lifespans of patients.

Entresto suppresses excessive activation of the ren1xbet 신청-angiotens1xbet 신청-aldosterone system (RAAS), one of the factors that exacerbate the pathology of heart failure. Additionally, Entresto is compensatory for RAAS by enhanc1xbet 신청g the endogenous natriuretic peptide system and correct1xbet 신청g imbalanced neurohumoral factors as a s1xbet 신청gle agent. As such, the drug represents a new approach 1xbet 신청 the treatment of chronic heart failure.

Novartis Pharma and 1xbet 신청 will jointly provide information on Entresto to medical professionals across Japan.

Newly approved 1xbet 신청, Entresto has received regualtory approval in more than 100 countries worldwide.

References

1. 1. 1
      1. The Japanese Circulation Society/Japanese Heart Failure Association Jo1xbet 신청t Guidel1xbet 신청es: Acute and Chronic Heart Failure Cl1xbet 신청ical Practice Guidel1xbet 신청es (revised 2017)